AbbVie Inc. $ABBV Stock Holdings Increased by Munich Reinsurance Co Stock Corp in Munich

Key Points

• Munich Re increased its AbbVie position by 3.8% in the second quarter, adding 5,727 shares to own 157,348 shares valued at approximately $39.6 million. Institutional investors collectively hold 70.23% of AbbVie’s stock.
• AbbVie reported quarterly EPS of $3.65, exceeding expectations of $3.61, while revenue rose 10.2% year over year to $16.99 billion. The company also maintained its quarterly dividend at $1.73 per share, representing a 2.7% annualized yield.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $276.64, although risks include reliance on Skyrizi, Humira’s patent-related decline and an FDA setback for neurotoxin candidate trenibotE.

Munich Reinsurance Co Stock Corp in Munich raised its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 157,348 shares of the company's stock after buying an additional 5,727 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich's holdings in AbbVie were worth $39,595,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC lifted its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Burk Holdings LLC bought a new position in AbbVie during the second quarter worth $30,000. IFC & Insurance Marketing Inc. acquired a new position in AbbVie in the fourth quarter worth $31,000. Finally, Abound Financial LLC acquired a new position in AbbVie in the fourth quarter worth $32,000. Institutional investors own 70.23% of the company's stock.

AbbVie Price Performance

Shares of NYSE ABBV opened at $255.00 on Friday. The firm has a market capitalization of $450.52 billion, a PE ratio of 72.03, a P/E/G ratio of 1.13 and a beta of 0.29. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The business's fifty day moving average price is $254.54 and its two-hundred day moving average price is $230.76.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is presently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Qulipta migraine expansion: AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment met its primary and secondary endpoints, potentially opening a new indication and supporting intermittent use rather than continuous daily dosing. This could expand Qulipta’s commercial opportunity and reinforce AbbVie’s position in migraine care. AbbVie's migraine treatment meets late-stage study goal
• Positive Sentiment: Higher HSBC valuation: HSBC raised its price target for AbbVie to $315 from $300 while maintaining a Buy rating, signaling continued confidence in the company’s growth outlook and product pipeline. HSBC adjusts price target on AbbVie
• Positive Sentiment: Dividend maintained: AbbVie declared a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. The unchanged payout supports the stock’s income appeal and reflects continued shareholder-return capacity. AbbVie declares quarterly dividend
• Neutral Sentiment: Pipeline and portfolio developments: Coverage highlighted the growth of Skyrizi and Rinvoq, the planned $10.9 billion Apogee Therapeutics acquisition, an ADARx collaboration and updated real-world data from an eye-implant study. These initiatives may diversify future growth, but their financial impact remains dependent on execution, approvals and clinical outcomes.
• Negative Sentiment: Regulatory setback: The FDA issued a Complete Response Letter for trenibotE, AbbVie’s fast-acting neurotoxin candidate. The action may delay the product’s launch and add uncertainty around the aesthetics pipeline. FDA issues Complete Response Letter for AbbVie’s trenibotE
• Negative Sentiment: Concentration and valuation concerns: Analysts continue to monitor AbbVie’s reliance on Skyrizi and the long-term effects of Humira’s patent-related decline. With the stock trading at a relatively elevated earnings multiple, execution risks and slower-than-expected diversification could limit further upside.

Wall Street Analyst Weigh In

Several research firms have weighed in on ABBV. Evercore set a $235.00 target price on shares of AbbVie in a research note on Friday, May 15th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Tuesday, June 23rd. Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. HSBC boosted their price objective on shares of AbbVie from $300.00 to $315.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Cantor Fitzgerald raised their target price on shares of AbbVie from $265.00 to $285.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $276.64.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by insiders.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.